The BIO Protocol token surged 105% following the announcement that AI agent peptAI designed a candidate drug for ADHD in just 24 hours. This rapid development, which included eight validation steps and a molecule ready for wet-lab testing, sparked a wave of interest in decentralized science (DeSci) on crypto Twitter. Despite the excitement, the broader context reveals that AI-discovered drugs have yet to complete Phase III trials, which are crucial for determining therapeutic efficacy. While AI-driven drug discovery shows promise, with an 80-90% success rate in Phase I trials, these trials only assess safety, not effectiveness. Currently, no AI-designed drugs have received FDA approval, and the earliest projections suggest this might not happen until 2028. The recent surge in BIO Protocol's token, which saw $720 million in trading volume, highlights the crypto market's short attention span, contrasting with the lengthy clinical trial timelines required for drug approval.